Hot or Not, Stock Market Edition: 10/31/2025

Happy Halloween! Here are 2 treats (hot stocks) and 2 tricks (not-so-hot stocks) for you:

• Hot: Boston Scientific (BSX) is basking in gains; MiMedX (MDXG) stands out in a volatile sector
• Not: HSBC Holdings (HSBC) is visited by the ghost of financial crimes past; Berkshire Hathaway (BRK.B) gets a downgrade

P.S. Don’t miss our recent story on 2 timely “buy the dip” stocks — get the tickers here

🔥 HOT: Boston Scientific (BSX) is lighting up the medical device sector — and basking in multi-year double-digit gains. Analysts are buzzing about strong operational execution and broad-based growth — especially in international markets. The Zen Rating for BSX stands tall at 89th percentile, earning a strong B overall with impressive Growth, Sentiment, Safety, and AI Component Grades all notching Bs. This balanced grade mix suggests not only consistent operational prowess but growing investor confidence. For a sector crowded with competition and market skeptics, Boston Scientific’s blend of global sales momentum and resilient earnings make it a solid pick. 

🥶 NOT: HSBC Holdings (HSBC) might be one of the world’s biggest banks, but that scale isn’t translating into shareholder excitement. Despite gaining 6% in the past week, the mini-rally feels fragile amid mixed earnings, lingering litigation, and cautious sentiment. (The real chill came from a $1.1 billion hit tied to a Madoff fraud ruling, a headline that froze investor confidence.) HSBC’s C-grade Zen Rating tells the story: middle-of-the-road fundamentals with C’s across most Component Grades — a lone B for Momentum being the only bright spot. But even that’s overshadowed by weak Growth and Safety scores and the Banking Industry’s current D rating (read more about Industry Grades here), signaling that any apparent value comes bundled with real risks. 

🔥 HOT: MiMedX (MDXG) isn’t a household name, but if you’re comfortable with a bit of biotech speculation, here are 3 big reasons why it should be on your radar. 1) The stock is jumping following earnings — according to WallStreetZen’s “Why Price Moved” feature, MDXG shares are trading higher after the company reported Q3 results above estimates. 2) Based on the aforementioned report, the company shows strong signs of operational momentum, healthy margins, and a niche in a growing healthcare segment. 3) A solid Zen Rating and Component Grades: Not only did MDXG just get upgraded to an A (Strong Buy) rating, but the Component Grades reveal several areas of strength with A grades for Sentiment and Financials. Biotechs aren’t for everyone, but if you can stomach a bit of risk, MDXG looks watchlist-worthy. 

🥶 NOT: Berkshire Hathaway (BRK.B) may be a pillar of American capitalism, but lately, the stock’s story looks more sleepy than spectacular. Here’s why: 1) BRK.B has been drifting sideways — with limited price momentum even as the broader market pushes higher. 2) Its Zen Rating was just downgraded to D (Sell), with middling Component Grades — C for Growth, C for Momentum, and C for Sentiment — signaling that investors may see better near-term upside elsewhere. (See more stocks to sell here)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.